Zacks Investment Research
26 Aug 2026, 14:55 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
The phase III INTerpath-001 study for Merck and Moderna's personalized cancer therapy combo met its primary endpoint of recurrence-free survival in high-risk melanoma patients. — Successful phase III trials for high-risk cancer treatments are major catalysts for stock price appreciation and future revenue streams.
+0.60Keytruda is scheduled to lose patent exclusivity in 2028. — The looming 'patent cliff' creates a long-term valuation headwind as cheaper generics will eventually erode monopoly pricing.
-0.40Merck's Keytruda recorded $16.40 billion in sales in the first half of 2026, representing a 4.2% year-over-year increase. — Strong current revenue growth confirms the continued market dominance of Merck's primary profit driver.
+0.30Continue reading
6 related stories
Search tags
Merck is utilizing a strong pipeline, new product launches, and recent acquisitions to mitigate the eventual loss of Keytruda's exclusivity. — Strategic diversification reduces the risk profile associated with the 2028 patent expiration.
+0.20Which stocks this story touches
Shares hit a 52-week high following positive phase III study data for a cancer therapy and strong pipeline growth prospects.
Positive top-line data from the INTerpath-001 study for its personalized cancer therapy combo.
Mentioned as a competitor to Merck's blockbuster drug Keytruda.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Accesswire
8h ago
